GlassScriptPhysician profile
Alysha Petroff
NPI 1073397204
$2,360.86
in general payments reported to CMS, 2019-2025
40 companies · $1,886 in 2025
The $1,886 reported for 2025 was more than what 93% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $95.68 · 2024: $379 · 2025: $1,886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,262 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.86 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $302.03 | 2025 | Zynyz, Monjuvi, Jakafi |
| Medtronic, INC. | $189.42 | 2023-2025 | Interstim |
| Sumitomo Pharma America, INC. | $173.84 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $152.91 | 2025 | |
| Daiichi Sankyo INC. | $107.84 | 2025 | Enhertu, Datroway, Vanflyta |
| Glaxosmithkline, LLC. | $107.26 | 2025 | Ojjaara, Zejula, Jemperli |
| Novartis Pharmaceuticals Corporation | $102.58 | 2025 | |
| Teleflex LLC | $96.96 | 2023-2025 | Urolift, Barrigel |
| Takeda Pharmaceuticals U.S.A., INC. | $87.60 | 2025 | Fruzaqla, Iclusig, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $78.63 | 2025 | Libtayo |
| Merck Sharp & Dohme LLC | $70.27 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals LP | $63.32 | 2025 | Enhertu, Imfinzi |
| Immunocore Limited | $58.22 | 2025 | Kimmtrak |
| Astellas Pharma US INC | $52.59 | 2025 | Vyloy |
| Abbvie INC. | $48.15 | 2024-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Geron Corporation | $43.02 | 2025 | Rytelo |
| Boston Scientific Corporation | $41.09 | 2025 | Ams 700 |
| Janssen Biotech, INC. | $40.17 | 2025 | Erleada, Talvey, Darzalex |
| Sobi, INC | $39.96 | 2025 | |
| Alexion Pharmaceuticals, INC. | $39.00 | 2025 | Ultomiris |
| Procept Biorobotics Corporation | $37.69 | 2024 | Aquabeam System |
| Stemline Therapeutics INC. | $34.48 | 2025 | Orserdu |
| Tolmar, INC. | $33.49 | 2024-2025 | Eligard |
| Adc Therapeutics America, INC. | $32.47 | 2025 | |
| Iovance Biotherapeutics, INC. | $28.63 | 2025 | Amtagvi |
| Emd Serono, INC. | $25.57 | 2025 | |
| Coloplast Corp | $24.65 | 2025 | |
| Telix Pharmaceuticals | $22.40 | 2025 | Illuccix |
| Array Biopharma INC | $21.69 | 2025 | Mektovi, Braftovi, Lorbrena |
| Tersera Therapeutics LLC | $21.62 | 2025 | Zoladex |
| Endo Pharmaceuticals INC. | $21.24 | 2024 | Xiaflex, Aveed |
| Urogen Pharma, INC. | $21.00 | 2023 | |
| Azurity Pharmaceuticals, INC. | $20.91 | 2025 | Danziten |
| Novocure INC. | $19.29 | 2025 | Optune Lua (Novottf-200t) |
| Dendreon Pharmaceuticals LLC | $18.34 | 2025 | Provenge |
| Celgene Corporation | $18.23 | 2025 | Reblozyl |
| Verity Pharmaceuticals INC. | $17.40 | 2024 | Trelstar |
| Genentech USA, INC. | $16.67 | 2025 | Itovebi |
| Springworks Therapeutics, INC. | $15.72 | 2025 | Ogsiveo |
| Axonics, INC. | $14.51 | 2024 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alysha Petroff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.